Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis

Savino, Costanza; Pedotti, Rosetta; Baggi, Fulvio; Ubiali, Federica; Gallo, Barbara; Nava, Sara; Bigini, Paolo; Barbera, Sara; Fumagalli, Elena; Mennini, Tiziana

doi:10.1016/j.jneuroim.2005.10.016

Cited by 104 publications

(94 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several distinguished investigations addressed the properties of the EPO to mediate protection against retinal damage through anti-apoptotic, 29,30 anti-oxidant, 22 and antiinflammatory 26,31 actions in hypoxia-, light-, and geneticinduced models. 5,8,12,15 Furthermore, Chung et al 20 reported on his finding for the expression of EPO and Figure 2 The role of erythropoietin in eye development via anti-apoptotic action.…”

Section: The Role Of Epo In the Eyementioning

confidence: 99%

“…The brief binding of asialoEPO to EPOR and the specificity of CEPO on retinal neurons may suggest suitable indication for AMD and DR. 31,82,90,105 We foresee that more clinical trials will be conducted to address on the bio-distribution, safety and efficacy of these new derivatives or peptide (peginesatide) 106 before delineating their optimal use in ocular disorders. So far, Hallym University Medical Center is sponsoring a clinical trial (NCT01131533) to determine the intraocular pharmacokinetics following single intravitreal injection of epoietin alfa.…”

Section: Future Directionsmentioning

confidence: 99%

“…130,131 The use of MSCs as a vector to deliver EPO 132 through intravenous injection for ocular disorders is feasible in the future as these cells could home into the inflammatory site 133,134 and cross the BRB. 7,31,[33][34][35] The presence of EPO in stem cells could also enhance the survivability of transplanted cells 128,135 in local (intraocular) site of injection. Guan et al 76 has compared the effect of transplantation of MSCs and EPO gene-modified MSCs subretinally in a rat model of retinal degeneration.…”

Section: Future Directionsmentioning

confidence: 99%

See 2 more Smart Citations

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

Erythropoietin (EPO) is a glycoprotein hormone conventionally thought to be responsible only in producing red blood cells in our body. However, with the discovery of the presence of EPO and EPO receptors in the retinal layers, the EPO seems to have physiological roles in the eye. In this review, we revisit the role of EPO in the eye. We look into the biological role of EPO in the development of the eye and the physiologic roles that it has. Apart from that, we seek to understand the mechanisms and pathways of EPO that contributes to the therapeutic and pathological conditions of the various ocular disorders such as diabetic retinopathy, retinopathy of prematurity, glaucoma, age-related macular degeneration, optic neuritis, and retinal detachment. With these understandings, we discuss the clinical applications of EPO for treatment of ocular disorders, modes of administration, EPO formulations, current clinical trials, and its future directions.

show abstract

Section: The Role Of Epo In the Eyementioning

confidence: 99%

Section: Future Directionsmentioning

confidence: 99%

Section: Future Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Revisiting the role of erythropoietin for treatment of ocular disorders

Ding

Leow

Munisvaradass

et al. 2016

Eye

View full text Add to dashboard Cite

show abstract

“…33,67,[91][92][93][94][95][96] Neuronal damage associated with cerebral malaria and radiosurgically-induced brain injury in mice can also be reduced by EPO and CEPO. [97][98][99] Translational relevance of these data is emphasized by a recent clinical study demonstrating that high plasma levels of EPO are associated with reduced risk of neurological sequelae in children with cerebral malaria.…”

Section: Neuroinflammation Retinal Disease and Peripheral Nerve Damagementioning

confidence: 99%

“…41,[101][102][103][104][105] In these conditions, the anti-cytokine, antiapoptotic, anti-oxidative, and trophic effects on both neurons and oligodendrocyte progenitor cells are likely to reduce inflammation and preserve myelination and neuronal function. 33,67,[91][92][93][94][95][96][97][98]102,103 The initial observation by Grimm et al 106 of a potent neuroprotective effect of EPO in light-induced retinal degeneration has been confirmed in many other models of retinal disease in which EPO derivatives are in consideration for clinical use. 7,106 -109 Here, a local intravitreal administration has been proposed to avoid neovascularization and angiogenesis after systemic EPO therapy.…”

Section: Neuroinflammation Retinal Disease and Peripheral Nerve Damagementioning

confidence: 99%

Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System

et al. 2009

View full text Add to dashboard Cite

Summary:The growth factor erythropoietin (EPO) and erythropoietin receptors (EPOR) are expressed in the nervous system. Neuronal expression of EPO and EPOR peaks during brain development and is upregulated in the adult brain after injury. Peripherally administered EPO, and at least some of its variants, cross the blood-brain barrier, stimulate neurogenesis, neuronal differentiation, and activate brain neurotrophic, antiapoptotic, anti-oxidant and anti-inflammatory signaling. These mechanisms underlie their tissue protective effects in nervous system disorders. As the tissue protective functions of EPO can be separated from its stimulatory action on hematopoiesis, novel EPO derivatives and mimetics, such as asialo-EPO and carbamoylated EPO have been developed. While the therapeutic potential of the novel EPO derivatives continues to be characterized in preclinical studies, the experimental findings in support for the use of recombinant human (rh)EPO in human brain disease have already been translated to clinical studies in acute ischemic stroke, chronic schizophrenia, and chronic progressive multiple sclerosis. In this review article, we assess the studies on EPO and, in particular, on its structural or functional variants in experimental models of nervous system disorders, and we provide a short overview of the completed and ongoing clinical studies testing EPO as neuroprotective/neuroregenerative treatment option in neuropsychiatric disease.

show abstract

Neuroprotective and Neurogenic Effects of Erythropoietin

Lehmann

Höke

2011

Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis

View full text Add to dashboard Cite

Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis

Cited by 104 publications

References 59 publications

Revisiting the role of erythropoietin for treatment of ocular disorders

Revisiting the role of erythropoietin for treatment of ocular disorders

Therapeutic Potential of Erythropoietin and its Structural or Functional Variants in the Nervous System

Neuroprotective and Neurogenic Effects of Erythropoietin

Contact Info

Product

Resources

About